News Releases

Dec 01, 2020
Biodesix Publishes Extended Analyses of the Nodify XL2® Lung Nodule Test
Assessment Confirms Test Performance After Two Years of Surveillance BOULDER, Colo. --(BUSINESS WIRE)--Dec. 1, 2020-- Biodesix, Inc. (Nasdaq: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced publication of an analysis of the company’s Nodify XL2
Oct 30, 2020
Biodesix Announces Closing of Initial Public Offering
BOULDER, Colo. --(BUSINESS WIRE)--Oct. 30, 2020-- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds to Biodesix , before deducting
Oct 28, 2020
Biodesix Announces Pricing of Initial Public Offering
BOULDER, Colo. --(BUSINESS WIRE)--Oct. 28, 2020-- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix”) today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on The Nasdaq
Sep 30, 2020
Big Ten Conference Partners with Biodesix, Inc. and Quidel Corporation
Biodesix, Inc. to oversee onsite surveillance testing of Quidel Corporation’s rapid SOFIA 2 SARS Antigen FIA test All involved in close contact Big Ten Conference sport competition to receive Quidel rapid antigen surveillance testing with additional validity testing through the Biodesix Laboratory
Jul 19, 2020
Biodesix Appoints Jean Franchi and Hany Massarany to Board of Directors
BOULDER, CO, July 16, 2020  -  Biodesix, Inc ., a leader in lung cancer diagnostics, today announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors. Ms. Franchi has more than 30 years of biotechnology and life science industry experience ranging from